Back to articles

The Cold Chain Shattered: Aphios Unveils Game-Changing Room-Temp COVID Vaccine!

Noah Williams•May 28, 2025
A dynamic graphic showing an mRNA strand being doubly encapsulated, first by lipid nanoparticles and then by a polymer nanosphere, with a backdrop transitioning from an icy, restrictive environment to a warm, accessible global map.
  • A single shot, stable at room temperature, poised to revolutionize global vaccination.
  • Aphios’ newly patented tech defeats ultra-cold storage, multiple doses, and PEG allergy fears2, 5.
  • This breakthrough paves the way for equitable vaccine access and robust future pandemic defense1, 3.

The era of vaccine ice ages may be over. Aphios Corporation has just been granted a U.S. patent for a technology that could redefine our fight against COVID-19 and future pandemics2, 5. Imagine a world free from the tyranny of ultra-cold freezers and complex supply lines that have hampered global vaccination efforts.

Aphios’ groundbreaking solution is a single-shot mRNA vaccine, ingeniously designed to remain potent at room or refrigerator temperatures. This marvel is achieved through a proprietary double nanoencapsulation system: mRNA, the vital code for our body's defense, is first nestled within lipid nanoparticles (LPN) or phospholipid nanosomes, then further shielded by biodegradable polymer nanospheres using Aphios’ green SuperFluids™ technology2, 5. This microscopic fortress not only ensures stability but also allows for an extended release of antigenic material, promising longer-lasting immunity and reducing the need for boosters2, 3.

Current mRNA vaccines, despite their efficacy, are shackled by -70°C or -20°C storage, multiple doses, and concerns over PEG-related hypersensitivity2, 5. Aphios’ innovation directly tackles these hurdles. “This patent marks a major step forward...to make vaccines more accessible, practical, and safer for people worldwide,” declared Dr. Trevor P. Castor, Aphios' CEO. By eliminating cold chain barriers and being PEG-free, this platform is set to empower regions lacking advanced medical infrastructure1, 7.

This isn't just about COVID-19. Aphios' NIH-backed, sustainably manufactured technology promises a new dawn for tackling other infectious diseases, making robust global health a more attainable reality1, 3.

References

  1. aphios.com
  2. www.biospace.com
  3. www.businesswire.com
  4. adisinsight.springer.com
  5. www.businesswire.com
  6. www.biospace.com
  7. aphios.com
  8. www.bioprocessingsummit.com

Stay Updated!

Get the latest biotech and pharma news delivered to your inbox.